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Abstract: Hematological and oncological disorders represent leading causes of childhood mortality.
Neuropeptide somatostatin (SST) has been previously demonstrated in various pediatric tumors,
but limited information exists on the expression and characteristics of SST receptors (SSTR) in
hematological and oncological disorders of children. We aimed to investigate the expression of
mRNA for SSTR subtypes (SSTR-1–5) in 15 pediatric hematological/oncological specimens by RT-PCR.
The presence and binding characteristics of SSTRs were further studies by ligand competition
assay. Our results show that the pediatric tumor samples highly expressed mRNA for the five
SSTR subtypes with various patterns. The mRNA for SSTR-2 was detected in all specimens
independently of their histological type. A Hodgkin lymphoma sample co-expressed mRNA for
all five SSTR subtypes. SSTR-3 and SSTR-5 were detected only in malignant specimens, such as
rhabdomyosarcoma, Hodgkin lymphoma, acute lymphoblastic leukemia, and a single nonmalignant
condition, hereditary spherocytosis. The incidence of SSTR-1 and SSTR-4 was similar (60%) in the
15 specimens investigated. Radioligand binding studies demonstrated the presence of specific
SSTRs and high affinity binding of SST analogs in pediatric solid tumors investigated. The high
incidence of SSTRs in hematological and oncological disorders in children supports the merit of
further investigation of SSTRs as molecular targets for diagnosis and therapy.
Keywords: hematological-oncological disorders in children; somatostatin receptors; somatostatin analogs
1. Introduction
Somatostatin is a widely distributed inhibitory peptide hormone that is involved in digestive,
endocrine, and immune functions. Somatostatin acts primarily as an inhibitor of cell proliferation
and hormone secretion with endocrine, paracrine, and autocrine activities. Somatostatin receptors
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(SSTR) are membrane-bound G-proteins that mediate physiological functions of somatostatin in the
body [1]. Overexpression of SSTR has been found in pituitary adenomas (PA) and many human
malignancies including lung, breast, and prostate cancers, colon carcinoma, glioblastoma, and uveal
melanoma [2–11]. SSTR are divided into five basic subtypes: SSTR-1 (SSTR-1 gene location 14q13),
SSTR-2 (17q24), SSTR-3 (22q13.1), SSTR-4 (20p11.2), and SSTR-5 (16p13.3). The antiproliferative action
of SST and high expression of their corresponding SSTRs on various endocrine tumors led to the clinical
application of synthetic stable analogs of SST for hormonal treatment of human malignancies such as
acromegaly [2,4,7]. Based on structural similarity and reactivity for octapeptide and hexapeptide SST
analogs, the receptor family can be divided into two subclasses: SSTR-2,3,5 react with SST octapeptide
analogs and constitute members of one subgroup; SSTR-1,4 react poorly with these compounds and
fall into another subgroup. [2,4,7,10–15]. Octapeptide analogs, such as octreotide (Sandostatin®),
somatuline (Lanreotide®), and octastatin (Vapreotide®) are very popular drugs and they show high
affinity to SSTR-2 and SSTR-5, moderate affinity to SSTR-3 and SSTR-4, and low binding affinity
to SSTR-1. It is reported that octreotide has the highest affinity to SSTR-2, then, approximately
similar affinity to SSTR-5 and SSTR-3, following lower binding affinity to SSTR-1, and displaying
the lowest to SSTR-4. However, Lanreotide shows the highest affinity to SSTR-2 similarly to SSTR-5
and somehow lower binding affinity to SSTR-3 and SSTR-4, and displays the lowest affinity to
SSTR-1. [12–15] Another novel SST analog pasireotide (SOM 230) possesses an affinity to SSTR-1,
SSTR-3, and SSTR-5 [1]. In addition, synthetic SST analogs found other useful clinical applications as
carrier molecules for radionuclides for tumor visualization and targeted radio- and chemotherapy of
SSTR-positive tumors [2,4,7].
The high expression of SST-14 and somatostatin receptors in childhood neuroblastoma and
medulloblastoma samples, as well as the clinical applicability of somatostatin receptor scintigraphy
and radioreceptor-guided surgery have already been described [12–16]. Pediatric hematological and
oncological diseases represent the second most frequent cause of childhood mortality after accidents,
consequently, there is an urgent need for improved methods for early detection and development
of novel treatment options of these disorders. Although the presence of SST has previously been
demonstrated in certain pediatric tumors [17], only very limited information exists about the expression
and characteristics of SSTRs in pediatric hematological and oncological disorders including malignant
and benign conditions.
Fibrous dysplasia (FD) of bone is a genetic, non-inherited, rare benign bone disease existing
in monostotic and polyostotic forms. FD is a developmental disease of bone in which there is
replacement of normal spongiosa and filling of the medullary cavity of affected bones by abnormal
fibrous tissue that contains trabeculae of poorly calcified primitive bone formed by osseous metaplasia.
Infantile myofibromatosis (IM) is a mesenchymal disorder described by fibrous proliferation of the skin,
bone, muscle, and viscera [18]. Although rare, it is the most common fibrous tumor in childhood [18–20].
Aggressive pediatric myofibromatosis is an autosomal recessive disease characterized by fibroblastic
proliferation from cells derived from muscle-aponeurotic tissue. Its etiology is unknown, and the
mean age of the reported cases is 7 years. The tumor shows rapid growth without serious pain
and appears to be attached to the muscle tissue and/or bone. The treatment option is typically
conservative surgical excision; however, early relapses have been reported [21]. Teratomas are special
tumors with various cellular components that contain mature (i.e., benign) or immature (malignant)
proliferating pluripotent cells of more than one germ-cell layers in origin. The incidence of teratomas
is 1:4000 births [22]. The etiology of teratomas is not fully understood; however, they are likely to
occur in part when individual pluripotent cells do not complete migration and continue dividing in an
abnormal location, typically along the midline [23]. Regarding their nature, teratomas can be both
benign and neoplastic. Mesenchymal hamartoma is a tumor-like benign mass of disorganized tissues
reflecting a local developmental malformation with a poorly understood pathogenesis. It is uncommon
in older children, especially after 2 years of age. The diagnosis of this tumor is difficult because the
signs and clinical symptoms may be nonspecific; therefore, a high index of suspicion is required for
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diagnosis and treatment. Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma among
children, with an annual incidence of 4.5 cases per 1 million children and is the third most frequent
extracranial solid tumor of childhood after neuroblastoma and Wilms tumor [24]. RMS tumors are
typically associated with the skeletal muscle lineage, and about 50% of cases are diagnosed in the first
decade of life. Acute lymphoblastic leukemia (ALL) is the most frequent hematological neoplastic
disease in children, characterized by the proliferation of transformed lymphoid cells in the bone
marrow, peripheral blood, and other organs. The age-adjusted incidence rate of ALL in the United
States is 1.38/100,000 individuals per year [25,26] with an estimated 5930 new cases and 1500 deaths in
2019 [26]. ALL accounts for 75–80% of acute leukemias in children [27,28]. Hodgkin lymphoma (HL)
is a highly curable form of childhood cancer, with estimated 5-year survival rates exceeding 98% after
treatment with chemotherapy alone or combined with radiotherapy (RT). Hereditary spherocytosis
(HS) is the most frequent congenital red blood cell membrane defect in which abnormalities of red
blood cell structural proteins lead to loss of erythrocyte membrane surface area, resulting in spherically
shaped, hyperdense, poorly deformable red blood cells accompanied by hemolysis. Incidence of HS is
1/5000 among individuals of European descent and in the United States. Immune thrombocytopenia
(ITP) is one of the most common bleeding disorders during childhood, occurring in ~5 to 10 per
100,000 children per year [27]. ITP in childhood is often a self-limited condition. Granulocytopenia
is a heterogenous group of disorders accompanied by a decrease in peripheral blood granulocytes
below the lower limit of normal range (<0.5 × 109/l) [29,30]. Chronic benign neutropenia is the most
common neutropenia in childhood. Neutropenia can be considered chronic if it does not improve after
8 weeks. In most children, neutropenia may persist for a few years and then resolve spontaneously.
Children with chronic benign neutropenia are generally healthy and have a normal physical exam.
In the current study, we aimed to investigate the expression of mRNA for somatostatin receptor
subtypes in a cohort of pediatric hematological and oncological specimens using RT-PCR and the
binding characteristics of SSTR protein by ligand competition assays. In addition, we analyzed the
correlation among the expression pattern of SSTR subtypes and clinicopathological characteristics of the
pediatric patients. To the best of our knowledge, this is the first report showing the expression of SSTRs
in various childhood tumors and hematological disorders. Our results may open up a new avenue for
potential diagnostic and therapeutic applications of somatostatin analogs in pediatric oncology.
2. Results
2.1. Expression of SSTRs in Human Pediatric Solid Tumors and Hematological Diseases
We performed subtype-specific RT-PCR analyses on 15 pediatric hematological and oncological
samples to investigate the mRNA expression of SSTR subtypes. The expected size of PCR products
amplified with gene-specific primers was 216 bp for SSTR-1, 168 bp for SSTR-2, 188 bp for SSTR-3,
222 bp for SSTR-4, and 191 bp for SSTR-5, respectively (Figure 1). The mRNA expression pattern of the
five SSTR subtypes examined, as well as the receptor binding characteristics of solid tumors and sample
types for the human specimens are shown in Table 1. We found that the pediatric samples investigated
highly expressed mRNA for the five subtypes of somatostatin receptors. The mRNA expression of
SSTR-2 subtype was detected in all (15/15) of the samples independently from their histological type.
Of the 15 specimens, only a HL sample expressed mRNA for all five SSTR subtypes and IM, FD,
and ITP showed only one receptor subtype, SSTR-2. The expression of SSTR-5 was detected in two
malignant solid tumor specimens (case 4, HL, and case 5, RMS). Of the 15 pediatric hematological
and oncological specimens, PCR products for SSTR-3 could be detected only in malignant samples,
two solid tumors (HL and RMS) and two cases (ALL and HS) expressed SSTR-3. Subtypes SSTR-3
and SSTR-5 were expressed in lower number of the specimens, found only in four and two samples,
respectively. The incidence of SSTR-1 and SSTR-4 was similar (9/15, 60%) in the 15 specimens analyzed.
Among all nine SSTR-4-positive samples, two were rhabdomyosarcomas, two specimens were ALL,
one was HL, one was teratoma type, one histologically was defined as hamartoma, one as HS, and one
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was chronic benign neutropenia. Both RMS samples in our study mostly showed positivity for SSTR-1,
SSTR-2, and SSTR-4. Both solid benign tumor samples showed SSTR-2 receptor expression, but none
of them expressed SSTR-3 and SSTR-5 (Table 1). Template-free and reverse transcriptase-free controls
excluded nonspecific amplification and DNA contamination. PCR amplification with specific primers
for β-actin produced a single product in every sample, confirming no RNA degradation in the samples.
As a positive control, human pituitary samples were used. (Figure 2)
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Figure 1. Representative RT-PCR analysis of mRNA for somatostatin receptor (SSTR) subtypes
(SSTR-1–5) in one representative pediatric Hodgkin lymphoma specimen. M: DNA marker 50 bp;
P: Positive control (human bladder carcinoma); N: Negative template control; T: Pediatric tumor
specimen (patient number 4, Hodgkin lymphoma) positive for all 5 SSTR subtypes (SSTR-1–5).
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Table 1. Expression of mRNA for somatostatin receptor subtypes (SSTR-1–5) and binding characteristic
of somatostatin receptors in pediatric hematological and oncological specimens.
Patient
Number
Sample Type SSTR-1 SSTR-2 SSTR-3 SSTR-4 SSTR-5
SSTR
Kd
(nM)
Bmax
(fmol/mg
Protein)
1 Teratoma - + - + - 5.76 274.0
2 Myofibromatosis - + - - - 6.85 273.3
3 Fibrous dysplasia - + - - - 4.94 255.1
4 Hodgkin lymphoma + + + + + 8.01 760.8
5 Rhabdomyosarcoma + + - + + 8.12 505.1
6 Rhabdomyosarcoma + + + + - 4.31 371.4
7 Hamartoma + + - + - 4.02 297.9
8 Acute lymphoblasticleukemia + + + - - N/A
9 Acute lymphoblasticleukemia + + - - - N/A
10 Acute lymphoblasticleukemia + + - - - N/A
11 Acute lymphoblasticleukemia - + - + - N/A
12 Acute lymphoblasticleukemia - + - + - N/A
13 Immunethrombocytopenia - + - - - N/A
14 Hereditaryspherocytosis + + + + - N/A
15 Chronic benignneutropenia + + - + - N/A
Kd and Bmax values were calculated from duplicates; Kd: dissociation constant; Bmax: maximal binding capacity;
N/A: not analyzed.
2.2. Radioligand Binding Studies
The presence of SSTR protein, characteristics of these SST-binding sites and specific binding of
radioiodinated SST analog RC-160 to membrane homogenates of human pediatric solid tumor samples
were determined using ligand competition assays. Of the seven specimens examined, five malignant
tumors and two benign tumor samples displayed SSTR binding (Table 1). Receptor binding affinities and
concentrations of SSTRs in tumor membranes were also studied. Analyses of the typical displacement
of [125I]RC-160 and the Scatchard plots of the specific binding data showed that the one-site model could
provide the best fit. Based on these receptor binding results, the presence of one class of high affinity
SSTR in crude membranes derived from human pediatric samples was indicated. The computerized
nonlinear curve-fitting program and the Scatchard plot analyses of the SST receptor binding data in
seven receptor-positive tumor samples showed that the single class of SSTRs had a mean dissociation
constant (Kd) of 6.00 nM (range 4.02–8.12 nM), with a mean concentration of SSTRs (maximal binding
capacity, Bmax) of 391.1 fmol/mg membrane protein (range 255.1–760.8 fmol/mg protein). Biochemical
specifications and parameters crucial to characterize specific binding sites were also defined. Thus,
the binding of [125I]RC-160 was detected to be specific reversible, temperature- and time-dependent,
and linear with protein concentration in the human pediatric tumor specimens examined. The specificity
of SST binding sites was also demonstrated in competitive binding assays. Various peptides structurally
Molecules 2020, 25, 5775 6 of 14
related or unrelated to SST were used in these studies. The binding of radioiodinated RC-160 was
displaced completely by increasing concentrations (10−12–10−6 M) of SST-14, whereas none of the
structurally and functionally different and unrelated peptides examined, such as epidermal growth
factor (EGF), luteinizing hormone-releasing hormone (LHRH), growth hormone-releasing hormone
(GHRH), [Tyr4]bombesin, and insulin-like growth factor I inhibited the binding of radiolabeled SST
octapeptide analog RC-160 at concentrations as high as 1 µM (Figure 3).
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Figure 3. Representative displacement of [125I]RC-160 binding to membrane fractions of human
rhabdomyosarcoma specimen by increasing concentrations of somat statin (SST) analog RC-160
(Vapreotide) (•), cytotoxic SST analog AN-162 (H) and RC-121, carrier peptide of AN-162 (#).
Other unrelated peptides like LHRH, GHRH, VIP, bombesin, and epidermal growth factor (∇) did not
displace the radioligand. Each point represents me n of duplicate or tripl cate determin t ons.
The expression of mRNA for SSTR subtypes was accompanied by ligand binding in all pediatric
tumor specimens examine . Comparative analysis of the results of radioreceptor assays and SSTR
subtype mRNA studies revealed that the expressi n of SSTR-2 and/or SSTR-5 subt pes was 100%
consistent with the presence of specific binding sites for [125I] RC-160 (Table 1.). The binding affinity of
SST analogs and cyt toxic SST anal g AN-162 t membrane rec ptors of human pediatric cancer cells
(HL and RMS) expressing SSTRs was also investigated by ligand competition assay. Displacement of
[125I] RC-160 as a radioligand by the unlabeled SST analogs as competitor was determined. Our results
show that SST oct peptide analogs RC-160 (vapreo ide) RC-121 (as carrier peptide of AN-162) and
cytotoxic SST analog AN-162 could effectively bind to SSTRs at low nanomolar concentration (Table 2,
Figure 3). Nevertheless, the cytotoxic SST conjugate AN-162 had only slightly lower binding affinity to
specific SSTRs than the free peptide carrier RC-121 (Table 2, Figure 3). Our results demonstrated that
the high binding affinity of the carrier peptide RC-121 to tumoral SSTRs was fully preserved in the
targeted cytotoxic analog of SST, AN-162.
Table 2. Receptor binding potency (IC50 values) of SST analogs to the membrane receptors of human
pediatric cancer cells.
Compound
IC50 Values (nM)
Hodgkin Lymphoma
(Patient No.4)
Rhabdomyosarcoma
(Patient No.5)
RC-160 (Vapreotide®) 0.86 0.73
RC-121 1.04 0.92
AN-162 1.53 1.19
IC50 values were calculated by computerized curve-fitting program from displacement experiments as described
earlier [6,8]. IC50 is defined as the dose causing 50% inhibition of specific binding of [125I] RC-160 to the membranes.
Values are means of two to three determinations.
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2.3. Patient Follow-Up
In the group of samples investigated, 5 children died within 5 years (2 patients with RMS,
one patient with teratoma, and two with ALL). The male to female ratio in the group investigated was
2:1 (10 boys, 5 girls). In the solid tumor group, four patients were still alive after 5 years, three children
died, and the male to female ratio was 1.33:1 (4 male and 3 female patients). In the hematological
diseases group, six patients were still alive after five years, two children with ALL died within 5 years
and the male to female ratio was 3:1 (6 male and 2 female patients) (Table 3). In our study, among the
five deceased patients, only two children showed relapse (both were ALL patients) that caused the
death of these patients.
Table 3. Clinicopathology data of 15 pediatric hematological and oncological specimens.
Sample Histological Type Gender Sample Type Age at SampleCollection
5-Year
Survival
1 Teratoma/adenocarcinomacomponent Male
Mediastinal
tumor tissue 14.5 year died
2 Juvenile myofibromatosis Male Right hip bonetumor tissue 2 year alive
3 Fibrous dysplasia Female Bone tumortissue 10.5 year alive
4 Hodgkin lymphoma Female Lymph node 15 year alive
5 Rhabdomyosarcoma Male Pelvic tumortissue 12.5 year died
6 Rhabdomyosarcoma Female Neck massbiopsy 8 year died
7 Benign mesenchymalhamartoma Male
Mediastinal
mass 4 year alive
8 Acute lymphoblasticleukemia Female Bone marrow 5 year alive
9 Acute lymphoblasticleukemia Male Bone marrow 13 year alive
10 Acute lymphoblasticleukemia Male Bone marrow 9.5 year died
11 Acute lymphoblasticleukemia Male Bone marrow 6.5 year alive
12 Acute lymphoblasticleukemia Male
Peripheral
blood 15 year died
13 Immunethrombocytopenia Male Bone marrow 10 month alive
14 Hereditary spherocytosis Female Bone marrow 9 month alive
15 Chronic benignneutropenia Male Bone marrow 12.5 month alive
We did not detect any significant correlation among somatostatin receptor expression pattern and
clinical outcome or clinicopathological characteristics.
3. Discussion
Despite stunning improvements since the mid-1990s, hematological and oncological diseases are
still among the leading causes of childhood mortality [31]. As compared to adult oncology, at this
moment, targeted oncotherapies play a much less important role among children with cancer. Moreover,
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combined chemotherapy protocols cannot be intensified any further without an unacceptable increase
in acute toxicity and late complications. Thus, there is an urgent need for improved methods of early
detection, accurate follow-up, and development of novel, effective treatment approaches based on
recently identified molecular targets.
Pediatric cancer is relatively rare, with less than 13,500 cases and approximately 1500 deaths per
year among children aged 0–14 worldwide [31]. Leukemia is by far the most common neoplastic disorder,
accounting for about 33% of childhood cancers, followed by brain tumors (25%), lymphomas (8%),
neuroblastoma (7%), and other rare pediatric malignancies such as Wilms tumor, soft tissue and bone
sarcomas, and germ-cell tumors with similarly low relative incidence [31]. Treatment of childhood
cancer depends on the type (histology and, ever increasingly, genotype) and the stage of the disease.
Common treatment approaches include chemotherapy, surgery, radiation therapy, and stem cell
transplantation. Innovative treatment modalities such as immunotherapy and targeted small molecular
drugs become more and more important elements of first-line treatment in pediatric oncology [26,31,32].
Tumor-associated peptides provide attractive properties for treatment strategies due to easy access,
convenient purification and storage. Furthermore, they are less immunogenic than antibody-based
immunotherapies, have high tissue penetration and high affinity to specific cellular targets that
influence cancer cell survival, proliferation, and differentiation [4,7,33]. They are characterized by a rapid
clearance from the body and are prominent candidates for straightforward conjugation strategies [4,7,33].
Demonstration of the antiproliferative action of peptide hormone SST and the presence of its SSTRs on
human endocrine tumors clearly led to the application of efficient and biologically stable synthetic
octapeptide analogs such as RC-160 (octastatin/Vapreotide®), SMS-201-995 (ocreotide/Sandostatin®),
SOM 230 (pasireotide), and BIM-23014 (somatuline/Lanreotide®) for hormonal treatment of these
malignancies [2,4,7,12,16]. These SST analogs are widely used for the treatment of acromegaly,
pancreatic neuroendocrine tumors, endocrine tumors of the gastroenterohepatic system, including
carcinoid tumors, glucagonomas, gastrinomas, insulinomas, and VIPomas [2,4,7,12,16,34]. Based on
our best knowledge, there are no definitive or conclusive data available in the literature showing
the potential activation of other receptors by these SST octapeptide analogs. In addition, it has been
demonstrated that SST analogs could be effectively used as carriers of radionuclides for visualization
and targeted radio- or chemotherapy of SSTR-positive tumors [4,7,16,35]. Many tumor cells of various
origins, such as well-differentiated gastroenteropancreatic neuroendocrine neoplasms as well as other
cancers show overexpression of SSTR, which can serve as the molecular basis of targeted diagnostic
and treatment methods [2,4,7,9,36]. The schematic SSTR-based potential downstream pathways and
signaling cascades leading to the modulation of hormone secretion, cell growth, and apoptosis are
shown in Figure 4.
Based on these findings, SST peptide analogs and SSTRs may have great diagnostic and therapeutic
potential in pediatric hematology and oncology. Similarly to adult oncology, radiolabeled somatostatin
analogs might offer an effective tool for identifying the localization and extent of tumors in children.
Very limited data are available on somatostatin analogs in childhood tumors. Most of these data
are not about malignancies, and almost all data were obtained with octreotide [38]. In addition,
Dishop and Kuruvilla reported that SST analogs are also used therapeutically to reduce the symptoms
and side-effects of chemotherapy and to induce differentiation in pediatric oncology [39]. It has not
been established whether SSTRs could be used for the localization and treatment of hematological
and oncological disorders in children and the previous findings available are incomplete and
inconclusive. Therefore, in our present study, we aimed to investigate the expression of mRNA
for SSTR subtypes (SSTR-1–5) in samples from human pediatric solid tumors as well as bone marrow
aspirates and peripheral blood of children with hematological diseases. We also studied the binding
characteristics of SSTR protein by radioreceptor assay. Moreover, we analyzed the potential correlation
among the expression of the SSTRs, their binding characteristics, and clinicopathological data of the
pediatric patients.
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Our results show that the 15 pediatric samples investigated highly expressed mRNA for all five
subtypes of SSTRs with various patterns. No sample was found without the expression of at least one of
the SSTR subtypes. It is noteworthy that only a HL sample expressed mRNA for all five SSTR subtypes.
Similarly, only SSTR-2 was observed in IM, FD, and ITP. Two malignant solid tumor specimens
showed the expression of SSTR-5 and PCR products for SSTR-3 could be detected only in malignant
samples. The incidence of SSTR-1 and SSTR-4 was similar (9/15, 60%) in the 15 specimens analyzed.
Among the nine SSTR-4 positive samples, two were RMS, two ALL, one was HL, one teratoma-type,
one histologically was defined as hamartoma, one as HS, and one as chronic benign neutropenia.
Among the five ALL samples, only the sample of the female patient was positive for SSTR-3, and none
of the four samples from male children expressed mRNA for SSTR-3. The very limited amount of
the biological samples did not allow us to perform Western blot or immunohistochemistry. However,
in seven cases we were able to prepare crude membrane protein fractions for radioligand binding
studies to demonstrate the presence of specific SSTR binding sites. Radioligand binding studies also
confirmed the presence of specific, high affinity SSTRs in pediatric solid tumors investigated with a
mean dissociation constant (Kd) of 6.00 nM and mean maximal binding capacity (Bmax) of 391.1 fmol/mg
protein. Molecular biology analyses and radioligand binding studies clearly demonstrated that the
expression of mRNA for SSTR-2 and SSTR-5 subtypes was 100% consistent with the presence of specific
receptors for radiolabeled SST octapeptide analog RC-160.
Although the size of the investigated cohort is rather small and its composition is heterogenous,
it is worth to note that in the examined group, five children with cancer died during the 5 year
follow-up period. Three of the five ALL patients were alive, but two children died within 5 years.
Patients diagnosed with rhabdomyosarcoma and teratoma showed the worst outcome in this cohort.
Correlation between SSTR expression and clinical data was not observed. The high binding affinity of
the synthetic octapeptide analogs to SSTR in malignant pediatric samples suggests that children with
SSTR-positive cancers might be good candidates for therapy with SST analogs, including the targeted
cytotoxic SST analog AN-162.
Our results demonstrated for the first time that somatostatin receptors are highly expressed in
childhood benign and malignant solid tumors and in samples of pediatric hematological disorders.
These findings might open up a new avenue for a potential application of peptide hormone analogs for
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the detection and treatment of pediatric oncological and hematological disorders. However, to clarify
the therapeutic and clinical significance of SST receptors in pediatric oncology and hematology,
further studies are needed. Our results may also help to better understand the exact mechanism of
pediatric hematological and oncological disorders and provide better approaches for the early detection
of these malignancies. Our findings may facilitate the potential clinical application of synthetic analogs
of somatostatin or its radionuclide or cytotoxic derivatives for diagnostic or therapeutic purposes.
4. Materials and Methods
4.1. Human Samples
We examined 15 pediatric hematological and oncological specimens. All available clinicopathological
data, including age at diagnosis, sex, tumor type or type of hematological disorder based on
histopathologic examination, sample type, and survival, are shown in Table 1. Average age of
patients was 8.03 years (range: 9 months–15 years). Human samples were collected from patients
treated at the Department of Pediatric Hematology-Oncology, University of Debrecen, Hungary.
Seven patients had solid tumors, eight children had malignant or benign type of hematological
disorders. Seven samples were bone marrow aspirates, one hematological specimen was obtained from
peripheral blood (Table 3). Solid tumor tissues were obtained at the time of primary surgery. All the
samples were processed for routine histopathological examination and the pathological diagnosis was
confirmed by a local pathologist. For molecular biology analysis, human bladder tumor tissue was
used as an SSTR-positive control. Local Institutional Ethics Committee approved the collection and
use of these specimens for the current study and informed consent was obtained. Tumor tissues were
immediately frozen in liquid nitrogen and stored at −80 ◦C until further processing. All diagnostic
interventions were performed based on suspected neoplastic conditions.
4.2. Histology
Histopathological examination of the 15 human pediatric hematological and oncological samples
involved in our study revealed that five patients were suffering from ALL. Two samples were classified
as RMS and one sample each was characterized histologically as teratoma, IM, FD, HL, hamartoma,
ITP, HS, and chronic benign neutropenia (Table 3).
4.3. RNA Isolation
Homogenization of the samples was performed with Tissue Ruptor (IKA®-WERKE GmbH).
Total RNA was isolated with an RNA Isolation Kit (Macherey-Nagel) according to the manufacturer’s
protocol. Isolated total RNA was redissolved in RNAs-free water and quantity and quality
were measured by a NanoDrop spectrophotometer (ND-1000, Thermo Fisher Scientific Inc.).
Whenever enough material was available, experiments were performed in triplicate.
4.4. RT-PCR Analysis of Total RNA Samples
Total RNA was analyzed using a MMLV kit (Promega Co., Madison, WI, USA). The reverse
transcriptase reaction mix (25 mM MgCl2; 10 × PCR buffer [500 mM KCl, 100 mM Tris-HCl, pH 8.3],
distilled, autoclaved water, 1 mM dinucleotides, 2.5 U/µL MuLV reverse transcriptase, 1 U/µL RNase
inhibitor, and 2.5 µM oligo dT) was added together with 200 ng RNA template. The total reaction
volume of 20 µL was incubated at 23 ◦C for 10 min and 42 ◦C for 15 min, followed by 99 ◦C for 5 min.
RT-PCR reaction was performed in 25 µL reaction volume with gene-specific primers. The primers
for PCR amplification were designed using the published sequences for the respective genes as shown
in Table 4. Primer sequences with as small as possible homology among SST receptor subtypes were
selected as described before [6,8].
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Table 4. Sequences of SSTR-1, -2, -3, -4, -5 primers used for RT-PCR assay.
SSTR-1 sense 5′-TAT CTG CCT GTG CTA CGT GC-3’(1 exon)
SSTR-1 antisense 5’-GAT GAC CGA CAG CTG ACT CA-3′(1 exon)
SSTR-2 sense 5′-CGG AGT GAC AGT AAG CAG GA-3′(1 exon)
SSTR-2 antisense 5′-CGA AGC CAG TGT GGG TAGG-3′(1 exon)
SSTR-3 sense 5’-TGA GTC ACC AAC GTC TAC ATCC-3’(1 exon)
SSTR-3 antisense 5’-ACG CTC ATG ACA GTC AGG C-3’(1 exon)
SSTR-4 sense 5′-CGC TAC GCC AAG ATG AAG A-3′(1 exon)
SSTR-4 antisense 5′-AGA CAG AAG ACG CTG GTG AA-3′(1 exon)
SSTR-5 sense 5’-CGT CTT CAT CAT CTA CAC GG-3’(1 exon)
SSTR-5 antisense 5’-GGC CAG GTT GAC GAT GTT GA-3’(1 exon)
For PCR reaction mixture 1 × PCR buffer, 1 U of Taq Polimerase (Invitrogen), 1.5 mM of MgCl2,
200 µM of dNTP (Fermentas), 0.5 µM of each of the gene specific primers (SSTR-1, SSTR-2, SSTR-3,
SSTR-5), (Invitrogen), and 3 µL cDNS template was used in 25 µL reaction volume. For SSTR-4 RT-PCR
reaction 300 µM dNTP (Fermentas) was added and 3 µL cDNS template was used in 25 µL volume
as well.
PCR reaction was performed in a C1000 TM Thermal Cycler RT-PCR system (Bio-Rad Laboratories,
Inc.). To run the RT-PCR, the following PCR protocol was used:
• for SSTR-1, SSTR-2, SSTR-4, SSTR-5: denaturation (3 min at 94 ◦C), 40 cycles (94 ◦C for 45 s,
60 ◦C for 30 s and 70 ◦C for 90 s);
• for SSTR-3: denaturation (3 min at 94 ◦C) was followed by 40 cycles (94 ◦C for 45 s, 63 ◦C for
30 s and 70 ◦C for 90 s).
The PCR reaction was finished by a prolonged extension time of 72 ◦C for 10 min.
PCR products were separated in a 1.5% agarose gel containing GelRed and detected under UV
light, digitalized with AlphaDigiDoc™ RT (Alpha Innotech). To determine the size of the DNA, a 50 bp
DNA marker (Bioline) was used. To test the quality of the RT-PCR, β-actin was used as a positive
internal control for each of the transcribed RNA samples (Figure 2).
4.5. Radioligand Binding Studies
The radioiodinated derivatives of the RC-160 SST analogue were prepared by the chloramine-T
method and purified by reverse phase high-performance liquid chromatography (RP-HPLC) as
described previously [6]. Somatostatin receptor-binding assays were performed as described
previously [6] with some minor modifications, using in vitro ligand competition assays based
on the binding of [125I] RC-160 as a radioligand to membrane fractions of the pediatric samples.
This radioiodinated ligand has been well characterized and reported previously and has high affinity
for SSTR-2 and SSTR-5 [4]. Tumor membrane homogenates were incubated as competitors with
50,000–70,000 cpm radioiodinated RC-160 and 10−12–10−6 M nonradioactive peptides. After incubation
for 2 h, the binding reactions were stopped, and the bound ligand was separated and counted in a
gamma counter. The LIGAND-PC computer curve-fitting software of Munson and Rodbard was used
to determine the type of receptor binding, the dissociation constant (Kd), and the maximal binding
capacity of SSTRs (Bmax) [6,8]. The binding potencies of SST analogs and cytotoxic SST analog AN-162
to SSTRs were also determined by displacement of [125I]-RC-160 binding. The final binding affinities
were expressed as IC50 values. Protein concentration was determined by the method of Bradford using
a Bio-Rad protein assay kit (Bio-Rad Laboratories, Inc.).
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